Oblenio Bio - new company to Create a Tri-specific T-cell Engager for Autoimmune Disorders

Oblenio Bio is granted the only right to license LBL-051, a novel CD19xBCMAxCD3 tri-specific T-cell engager antibody, from Leads Biolabs.

On November 7, 2024, Aditum Bio and Leads Biolabs announced the formation of a new company, Oblenio Bio, in conjunction with an exclusive option and license agreement to develop LBL-051, a first-in-class CD19xB-cell maturation antigen (BCMA)xCD3 tri-specific T-cell engager antibody, for the treatment of autoimmune diseases. Oblenio Bio will get funding from Aditum Bio, a biotech venture firm based in the United States. The firms will work together with Leads Biolabs, a clinical-stage biotechnology startup based in Nanjing, China, to move LBL-051 forward quickly into clinical trials.

According to the deal, Leads Biolabs will give the newly created Oblenio Bio the exclusive right to develop, manufacture, and sell LBL-051 internationally. Leads Biolabs can expect to receive up to $35 million in upfront and near-term payments, $579 million in development, regulatory, and commercialization milestone payments, and sales royalties. Leads Biolabs is also eligible to obtain an ownership investment in Oblenio Bio.

"By targeting both CD19 and BCMA in autoimmune disorders, LBL-051 has the potential to achieve a complete immune reset and superior efficacy and durability, compared to single targeting of either CD19 or BCMA alone," said Joe Jimenez, co-founder and managing director of Aditum Bio, in a statement."LBL-051 provides a unique approach to treating specific autoimmune disorders and has the potential to be a Pipeline in Product. In the statement, Xiaoqiang Kang, MD, PhD, founder, chairman, and CEO of Leads Biolabs, stated that the company is thrilled to cooperate with the high-caliber team at Aditum to provide this revolutionary medicine to patients all around the world.

Oblenio Bio is Aditum Bio's thirteenth firm, formed as part of the company's objective to provide critical medications to huge patient populations. Aditum Bio promotes an incubator model that attempts to reduce time-to-market and focus on the translational phase of medication development. The corporation also in-licenses promising medical discoveries and spins off independent companies dedicated to moving each candidate through early clinical trials.
Leads Biolabs specializes on discovering and developing novel medicines to address large unmet medical needs in oncology, autoimmune diseases, metabolic disorders, and other critical ailments. The company's R&D pipeline contains over 20 unique candidates in a variety of modalities, including monoclonal antibodies, multi-specific antibodies, T-cell engagers, and antibody-drug conjugates.

Source: Aditum Bio